Utilization of EGFR, ALK, and BRAF Inhibitors in the Treatment of Lung Cancer in Germany
Nikolaj Rischke, Josephine Kanbach, Ulrike Haug · 2024
Read Utilization of EGFR, ALK, and BRAF Inhibitors in the Treatment of Lung Cancer in Germany by Nikolaj Rischke, Josephine Kanbach, Ulrike Haug (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11654761.txt.
Description
Targeted drugs that block specific mutations have changed lung cancer care, but little was known about how often they are used in routine practice in Germany. Rischke, Kanbach, and Haug used insurance claims covering about a fifth of the German population to follow 7,833 people diagnosed with lung cancer in 2016 through 2019. They counted who received inhibitors aimed at the EGFR, ALK, or BRAF pathways and described those patients.
Five percent of the patients, 392 people, got at least one of the drugs, and sixty-two percent of them were women. Most started on an EGFR inhibitor, and about half had chemotherapy first. Use was a bit higher in East Germany than in West Germany, at 6.2 percent against 4.8 percent. Median survival after the first targeted drug was twenty-two months. The authors call for updated use studies as new drugs keep arriving.
Catalog record
| CREATOR | Nikolaj Rischke, Josephine Kanbach, Ulrike Haug |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 32 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |